Accium BioSciences is a privately-held company offering ultra-sensitive bioanalytical services to the pharmaceutical industry. The company operates the first commercial Accelerator Mass Spectrometry (AMS) Core Facility in the U.S.

Accium offers pharmaceutical researchers specialty services that significantly reduce the time, cost and risk of advancing novel drugs from the laboratory to the clinic. According to the FDA, new medicinal compounds entering Phase 1 trials today stand only an 8% chance of reaching the market. Moreover, recent research breakthroughs have not improved the ability to select the best drug candidates to take to the clinic. Inability to predict failure in the clinic dramatically escalates drug development costs. The FDA has stated that a mere 10% improvement in predicting failure before clinical trials could save $100 million in development costs per drug.

For the first time, drug developers will be able to use Accium’s services to obtain clinical data on novel compounds prior to conducting a full-scale Phase 1 clinical study. These clinical data, combined with animal experiments, offer drug developers a more reliable toolset for selecting the best candidates to advance to Phase 1 trials. Drug candidates with inappropriate metabolism, such as a short half-life or poor bioavailability, can be eliminated early before significant amounts are spent in further clinical trials.

At the core of Accium’s facility is a National Electrostatics Model 1.5SDH-1 Pelletron Accelerator, a dual acceleration (tandem) electrostatic accelerator. This accelerator along with other associated items form an AMS system especially constructed to measure the amount of ¹⁴C in small biological samples.

Our Mission

Our mission is to quickly and efficiently drive the development of better pharmaceuticals by enabling critical decisions in early drug development.

Innovation and Leadership

In 1996, Accium’s founder, Dr. Ali Arjomand, designed and conducted the first AMS study involving human subjects in the U.S. The research required detailed design, planning, ethics board approval, methods development, laboratory analysis and mathematical modeling of the AMS results. The work was first presented at the 1997 Mathematical Models in Experimental Nutrition Conference. This research was carefully coordinated with Dr. John Vogel at Lawrence Livermore National Laboratory (LLNL) and Dr. Andrew Clifford at the University of California, Davis.